Table 2 Characteristics and outcomes of critically ill patients receiving ibrutinib with invasive fungal infection
Underlying malignancy and treatment line | Concomitant treatments and additional risk factors | Organ failure | Organ support | EORTC grade | Organ involvement | Anti-infective treatment | ICU outcome | Day-90 outcome | |
|---|---|---|---|---|---|---|---|---|---|
Aspergillosis | |||||||||
1 | CLL Second line | – | ARF | – | Probable | Lungs | VCZ | Death | Death |
2 | CLL Fourth line | CTC Diabetes | ARF ALF | IMV NAD | Probable | Lungs | VCZ AmB | Alive | Alive |
3 | CLL Second line | HypoƔ | ARF Shock AKI | IMV NAD RRT | Probable | Lungs | VCZ | Alive | Alive |
4 | CLL Second line | – | ARF | IMV NAD | Probable | Lungs | TMP-SMX VCZ | Alive | Alive |
5 | CLL First line | Diabetes | ARF Shock | IMV NAD RRT | Probable | Lungs | VCZ | Death | Death |
6 | CLL Third line | – | ARF | - | Probable | Lungs | VCZ | Alive | Death |
7 | CLL Third line | CTC | ARF | IMV NAD RRT | Probable | Lungs CNS | VCZ Caspo | Death | Death |
8 | CLL Second line | – | ARF Shock AKI | IMV NAD | Probable | Lungs | Caspo AmB | Death | Death |
9 | CLL Third line | Neutropenia Allo-HSCT | ARF Shock Coma | IMV NAD | Probable | Lungs | AmB | Death | Death |
Pneumocystis pneumonia | |||||||||
1 | CLL Second line | HypoƔ | ARF AKI | – | Probable | Lungs | TMP-SMX | Alive | Alive |
2 | DLBCL Second line | CTC Anti-CD20 | ARF Shock Coma | IMV NAD | Probable | Lungs | TMP-SMX | Alive | Death |
3 | DLBCL First line | Diabetes Anti-CD20 | ARF Shock | IMV NAD | Probable | Lungs | TMP-SMX | Alive | Alive |
Cryptococcosis | |||||||||
1 | CLL Fourth line | – | ARF ALF AKI | IMV RRT | Proven | Lungs | AmB 5FU FLZ | Alive | Death |